Telmisartan
From Wikipedia, the free encyclopedia
 |
|
|
Telmisartan
|
|
| Systematic (IUPAC) name | |
| 2-[4-[[4-methyl-6-(1-methylbenzoimidazol-2-yl)- 2-propyl-benzoimidazol-1-yl]methyl]phenyl] benzoic acid |
|
| Identifiers | |
| CAS number | |
| ATC code | C09 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C33H30N4O2 |
| Mol. mass | 514.617 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 42–100% |
| Protein binding | ≥99.5% |
| Metabolism | Minimal hepatic |
| Half life | 24 hours |
| Excretion | Faecal 97% |
| Therapeutic considerations | |
| Pregnancy cat. | |
| Legal status |
S4 (Au), POM (UK), ℞-only (U.S.) |
| Routes | Oral |
Telmisartan (INN) (pronounced /tɛlmɪˈsɑrtən/) is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. It is marketed under the trade names Micardis (Boehringer Ingelheim), Pritor or Kinzal (Bayer Schering Pharma), Telma (Glenmark Pharma), Telday (Torrent Pharmaceuticals) and Teleact D by (Ranbaxy).
[edit] Pharmacology
Generally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT1) receptors with high affinity, causing inhibition of the action of angiotensin II on vascular smooth muscle, ultimately leading to a reduction in arterial blood pressure.
New studies suggest that telmisartan may also have PPARγ agonistic properties that could potentially confer beneficial metabolic effects. This observation is currently being explored in clinical trials.
[edit] Clinical use
[edit] External links
- http://www.pritor.com
- http://www.micardis.com/com/index.jsp
- http://www.pslgroup.com/dg/e6dce.htm
- http://www.ICMAedu.com
|
|||||||||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
